Kidney involvement in systemic lupus erythematosus (SLE, lupus) is an important predictor of and contributor to morbidity and mortality from lupus. The approach to treatment for lupus nephritis is that of an induction phase of therapy (with cyclophosphamide vs mycophenolate mofetil) followed by long-term maintenance therapy. However, the optimal agent for chronic immunosuppression to prevent relapse or worsening of renal SLE is unknown. In the following study, recently published in the New England Journal of Medicine, mycophenolate mofetil and azathioprine were compared for the maintenance of remission in patients with lupus nephritis [Dooley MA, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. NEJM 2011;365:1886-95].
This was a prospective, randomized, double-blind, double-dummy phase 3 study of patients age 12-75 years with active class III, IV, or V lupus nephritis who successfully responded to induction therapy with mycophenolate mofetil or cyclophosphamide. Patients were then randomly assigned to mycophenolate mofetil or azathioprine for maintenance therapy and followed for 36 months. The primary end point was time to treatment failure. Treatment failure was defined as death, development of end-stage renal disease, sustained doubling of creatinine, renal flare, or the need for additional therapy in the context of lupus nephritis.
227 patients with lupus were randomly assigned to receive maintenance treatment with mycophenolate mofetil (n=116) or azathioprine (n=111). After 36-months, 73 patients in the mycophenolate group (63%) and 54 patients in the azathioprine group (49%) completed the study. Regarding the primary end point, time to treatment failure, there were fewer patients in the mycophenolate group (16.4%) compared to the azathioprine group (32.4%) and this was statistically significant [HR for treatment failure 0.44, 95% CI 0.25, 0.77]. The overall number of adverse events was similar between the two groups (p=0.68) with the most common being infection. A higher proportion of patients in the azathioprine group had adverse events which led to drug withdrawal (39.6%) compared to the mycophenolate group (25.2%).
Mycophenolate mofetil is superior to azathioprine for the maintenance of renal remission and the prevention of renal relapse in patients with lupus nephritis who responded to induction therapy (with either cyclophosphamide or mycophenolate mofetil).
Although this study demonstrates superiority of mycophenolate mofetil compared to azathioprine for maintenance of renal remission, it is important to recognize the study population in whom these data can be applied. Notably, this is a population of lupus patients who responded to induction therapy. Further, the study was not powered to note particular differences in subgroups. The subgroups which may be of particular interest in future investigations are the differential efficacy of mycophenolate and azathioprine among racial groups (Caucasian vs African American vs Asian, etc) and if there is a differential response among t
Receive the Latest News from Johns Hopkins Rheumatology
Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.